Glucomust M 5/500 Tablet

Drug | Tablet

Type 2 diabetes mellitus in adults with inadequate glycaemic control on metformin alone; add-on therapy when fasting and post‑prandial glucose remain elevated despite diet and exercise.

Glipizide closes pancreatic beta‑cell ATP‑sensitive K+ (KATP; SUR1) channels, depolarising the cell and increasing Ca2+ influx to trigger insulin release. Metformin activates AMP‑activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and improving peripheral insulin sensitivity while decreasing intestinal glucose absorption.

Glucomust M 5/500 Tablet is usually taken 1 tablet once daily with breakfast or the main meal initially; if prescribed twice daily, take with breakfast and dinner to reduce gastrointestinal upset and hypoglycaemia. Swallow whole with water; do not skip meals after taking the 5mg glipizide/500mg metformin combination.

Common: nausea, diarrhoea, abdominal discomfort, metallic taste, decreased appetite, hypoglycaemia (sweating, tremor, palpitations), weight gain, headache; Serious: lactic acidosis, severe/prolonged hypoglycaemia, cholestatic jaundice/hepatitis, blood dyscrasias (leukopenia, thrombocytopenia), severe skin reactions (SJS/TEN), angioedema.

Hypoglycaemia risk is higher with missed meals, heavy exercise, alcohol use, elderly patients, or renal impairment—carry fast‑acting glucose. Metformin component: monitor eGFR before start and periodically; dose review advised when eGFR 30–45 and avoid initiation; stop during dehydration, severe infection, or hypoxic states. Lactic acidosis warning—seek urgent care for rapid breathing, persistent vomiting, severe weakness, abdominal pain. Hepatic impairment increases lactic acidosis/hypoglycaemia risk. Pregnancy: insulin preferred for diabetes management; use only if clinician considers benefit > risk. Breastfeeding: metformin appears in milk in small amounts; glipizide may cause infant hypoglycaemia—medical advice required. Vitamin B12 deficiency can occur with long‑term metformin—periodic B12 assessment in anaemia/neuropathy.

Alcohol increases risk of metformin‑associated lactic acidosis and potentiates hypoglycaemia; iodinated contrast media can precipitate acute kidney injury leading to metformin accumulation/lactic acidosis; insulin or other antidiabetics (e.g., linagliptin, empagliflozin) additively increase hypoglycaemia risk; beta‑blockers (e.g., propranolol) mask adrenergic warning signs of hypoglycaemia; fluoroquinolones (e.g., levofloxacin) may cause dysglycaemia; corticosteroids/diuretics (prednisolone, hydrochlorothiazide) raise glucose and reduce efficacy; cimetidine reduces metformin renal clearance via OCT2/MATE inhibition increasing exposure; ACE inhibitors (e.g., enalapril) may enhance glucose‑lowering causing hypoglycaemia in some patients; NSAIDs may increase sulfonylurea effect and hypoglycaemia.

Store at 20–25°C; protect from moisture and direct light; keep in original blister pack.

Glycomet-GP 2 Tablet (Glipizide 5mg + Metformin 500mg); Glucored-GP 2 Tablet (Glipizide 5mg + Metformin 500mg); Glipimet 5/500 Tablet (Glipizide 5mg + Metformin 500mg)